Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 30 November 2023

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to regulate the supply and manufacture of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act provides the legal framework for the Therapeutic Goods Administration (TGA) to oversee these aspects, thereby protecting public health. This legislative measure was essential to fill the gap left by the need for stringent control and regulation over therapeutic goods to safeguard consumers from substandard, unsafe, or misrepresented products. The policy objective of the Act is to ensure that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy, thereby protecting public health. On 30 November 2023, Katherine Clark, a Delegate of the Secretary of the Department of Health and Aged Care and Therapeutic Goods Administration, published a notice regarding the revocation of a Licence to Manufacture Therapeutic Goods. This revocation, carried out under Section 41(1)(e) of the Therapeutic Goods Act 1989, affected ECO BOTANICALS PTY LTD, whose Licence (MI-14122004-LI-000308-1) was cancelled. This action exemplifies the TGA's commitment to maintaining high standards in the manufacture of therapeutic goods, ensuring that only compliant entities operate within the Australian market.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, supply, importation, or distribution of therapeutic goods within Australia. Therapeutic goods include medicines, medical devices, blood and blood components, tissues, and organs intended for human use. The Act also applies to therapeutic goods advertising and the promotion of these goods. The jurisdiction of the Act is national, covering all states and territories of Australia, with the Therapeutic Goods Administration being the Commonwealth authority responsible for its implementation. The Act provides for the regulation of therapeutic goods through licensing, registration, and other administrative measures to ensure that these goods are safe, of high quality, and effective. The Act does not apply to goods regulated under other federal legislation, such as food or cosmetics, which have their own specific regulatory frameworks. The Act's scope may be extended through subordinate instruments, such as regulations and guidelines, which provide further detail on specific aspects of the legislation, including manufacturing standards and advertising requirements. Exemptions and exclusions from licensing requirements may apply under certain conditions, such as for research purposes or for low-risk goods, as specified in the regulations.

Key Provisions

The main operative section of the notice (Gazette) under the Therapeutic Goods Act 1989 pertains to the revocation of a licence for the manufacture of therapeutic goods. Specifically, Section 41(1)(e) is referenced in the notice, which authorises the Secretary to revoke a licence if certain conditions are met (Section 41(1)(e)). In this instance, the Secretary has exercised this power to revoke the licence held by ECO BOTANICALS PTY LTD, identified by the licence number MI-14122004-LI-000308-1. The notice provides details of the revocation, including the name of the entity, its address, and the specific licence that has been revoked. The Therapeutic Goods Administration (TGA) imposes obligations on entities holding a licence to manufacture therapeutic goods. These obligations include, but are not limited to, ensuring the quality, safety, and efficacy of the manufactured goods. The TGA requires that manufacturers adhere to Good Manufacturing Practice (GMP) standards, maintain proper records, and comply with other regulatory requirements as stipulated in the Therapeutic Goods Act 1989 and associated regulations. The revocation of a licence indicates that the entity in question has failed to meet these obligations, potentially due to non-compliance with regulatory standards or other breaches of the Act. For breaches of the Therapeutic Goods Act 1989, there are various offences, penalties, and consequences that can apply. The severity of the penalties often depends on the nature and extent of the breach. For example, manufacturing therapeutic goods without a valid licence can result in criminal charges, with potential penalties including fines and imprisonment. The Act also provides for civil penalties, where the TGA can issue infringement notices for less severe breaches. The maximum penalties for criminal offences can include substantial fines and imprisonment terms, which are determined by the court based on the seriousness of the offence. The revocation of a licence itself serves as a significant consequence, potentially impacting the entity's ability to legally manufacture therapeutic goods in Australia.